AI summary · may contain errors
RAC1P29S metastatic melanoma cells engulf more Jurkat T cells than an isogenic RAC1WT revertant line, with live imaging revealing lamellipodial dynamics during whole-cell engulfment.
- Open access
Moving in Journal of Clinical Oncology, bioRxiv, Clinical Cancer Research, Journal of Investigative Dermatology, Cancer Discovery, Journal of Clinical Investigation, Molecular Cancer Therapeutics and Neuro-Oncology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
RAC1P29S metastatic melanoma cells engulf more Jurkat T cells than an isogenic RAC1WT revertant line, with live imaging revealing lamellipodial dynamics during whole-cell engulfment.
AI summary · may contain errors
MYBL2 overexpression on frequently amplified chromosome 20q promotes melanoma progression and poor survival, while its transactivation function is dispensable.
AI summary · may contain errors
Single-cell RNA sequencing and spatial multiomics have advanced melanoma research by resolving intra-tumoural heterogeneity and tumour microenvironment interactions linked to therapy resistance.
AI summary · may contain errors
In 29 patient-derived and established tumor spheroid models, pan-RAS(ON) daraxonrasib (RMC-6236) suppressed growth across diverse RAS alterations and wild-type RAS.
AI summary · may contain errors
Acral melanoma on palms, soles, and the nail apparatus shows low mutational burden but extensive structural genomic alterations, including CCND1 and TERT amplifications within clustered copy-number “hailstorms”/tyfonas.
AI summary · may contain errors
Glycoprotein nonmetastatic melanoma protein B overexpression is strongly upregulated in CDK4/6 inhibitor–resistant estrogen receptor-positive breast cancer models and predicts failure of CDK4/6 blockade.
AI summary · may contain errors
Ruxolitinib exposure is linked to aggressive cutaneous squamous cell carcinoma (cSCC) in pharmacovigilance and a large cohort, with mechanistic support from JAK2-driven MAPK activation.
AI summary · may contain errors
RMC-8839 selectively reduces viability in KRASG13C-mutant non-small cell lung cancer models, and combining it with docetaxel shows robust anti-proliferative activity in KRASG13C-driven in vitro and in vivo settings.
AI summary · may contain errors
Ulixertinib showed no objective responses (ORR 0%) in 34 pancancer patients with BRAF fusions or non-V600E/non-V600K BRAF mutations.
AI summary · may contain errors
Multimodal single-cell technologies enable simultaneous measurement of genotypes and phenotypes in primary human samples, revealing mutant-specific traits and genotype–phenotype links.
AI summary · may contain errors
Five-year survival rates with neoadjuvant immune checkpoint inhibitors reach up to 87.5% in melanoma patients, especially among those achieving major pathological response.
AI summary · may contain errors
FAK/SRC signaling mediates feedback activation of RAS/MAPK and AKT pathways after KRAS G12C inhibitor treatment, and FAK/SRC blockade resensitizes sotorasib-resistant cells.
AI summary · may contain errors
A Brazilian oncologist’s reaction to new daraxonrasib data is described through four encounters, highlighting how emerging evidence is received.
AI summary · may contain errors
Trametinib induces a robust senescent phenotype in BT-40 paediatric BRAF-V600E glioma tumours in vivo, and Navitoclax senolysis linked to BCL-xL inhibition ablates those cells.
AI summary · may contain errors
Cryo-EM structures show how MAP2K MEK1 activates MAPK ERK2, revealing substrate-driven release of MEK1 catalytic machinery and specificity at the final cascade step.
AI summary · may contain errors
Circulating thymidine kinase activity predicts survival in SECOMBIT trial patients with BRAF V600-mutated metastatic melanoma, with TKa-low showing 70.7% vs 36.9% overall survival.
AI summary · may contain errors
Cryo-EM structures show pMEK1 bound to unphosphorylated ERK1/2 and monophosphorylated ERK1 reveal how MEK1 enables dual phosphorylation and reverse dephosphorylation.
AI summary · may contain errors
Expert histopathologic evaluation plus molecular testing resolved 966 of 994 (97.2%) ambiguous primary cutaneous melanocytic tumors, with long-term outcomes supporting clinical validity.
AI summary · may contain errors
Nivolumab plus axitinib in untreated advanced mucosal melanoma achieved a 45% objective response rate (RECIST v1.1) in 20 evaluable Western patients.
AI summary · may contain errors
Daraxonrasib (RMC-6236) suppressed growth in patient-derived multi-cell type tumor spheroids across models with diverse RAS alterations and wild-type RAS, showing broad pan-RAS(ON) activity.
AI summary · may contain errors
Neoadjuvant intralesional Daromun (L19IL2/L19TNF) improved recurrence-free survival in fully resectable stage III melanoma, with hazard ratio 0.59 (P = .005) at 21 months.
AI summary · may contain errors
Progressive slate-gray skin discoloration (diffuse melanosis cutis) and darkening of urine occur in a case with advanced melanoma and 2 primary cutaneous melanomas.
AI summary · may contain errors
MutationProjector, a pre-trained genomic model, predicts therapeutic resistance and sensitivity across multiple cancer types with performance matching or exceeding state-of-the-art methods.
AI summary · may contain errors
Combined oncolytic viral therapy with MEK inhibition is associated with unexpectedly strong responses in checkpoint-failed NRAS-mutated melanoma.
Journals this month
Topics moving, week to 17 Nov 2026
By field